Trials / Completed
CompletedNCT02908087
Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- University of Oulu · Academic / Other
- Sex
- All
- Age
- 10 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the trial is to study whether daily treatment with liraglutide improves insulin secretion and reduces the requirement of exogenous insulin, and whether liraglutide treatment is tolerable and safe in subjects aged 10-30 years, having an early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT), and treated with insulin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Victoza® (liraglutide) | Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months. |
| DRUG | Placebo | Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months. |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2021-05-01
- Completion
- 2021-05-01
- First posted
- 2016-09-20
- Last updated
- 2022-01-11
Locations
4 sites across 2 countries: Finland, Sweden
Source: ClinicalTrials.gov record NCT02908087. Inclusion in this directory is not an endorsement.